Last reviewed · How we verify
NCT05455528
Preoperative Renal Insufficiency Predicts Postoperative Adverse Outcomes
trial testing estimated GFR calculation in Renal Insufficiency in 2,421,286 participants. Completed in 1 July 2022.
30 June 2022
Quick facts
| Lead sponsor | Taipei Medical University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,421,286 |
| Start date | 1 January 2022 |
| Primary completion | 30 June 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- estimated GFR calculation
Conditions studied
- Renal Insufficiency — all drugs for Renal Insufficiency →
- Morality — all drugs for Morality →
Sponsor
Taipei Medical University Hospital
Who can join
Eligibility, any sex, with Renal Insufficiency or Morality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to evaluate the risk of postoperative mortality and complications in surgical populations with preoperative renal insufficiency.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preoperative renal insufficiency predicts postoperative adverse outcomes in a mixed surgical population: a retrospective matched cohort study using the NSQIP database.
Liao YC, Chang CC, Chen CY, Liu CC, et al · · 2023 · cited 12× · PMID 36974714 · DOI 10.1097/js9.0000000000000278
Verify or expand the search:
- PubMed search for NCT05455528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Insufficiency
Currently open trials in the same condition.
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT07001436 — A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insuffici · Phase 1 · recruiting
- NCT06431789 — Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in P · recruiting
- NCT06354231 — DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC · Phase 2 · recruiting
- NCT05428631 — Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Ca · NA · recruiting
Other Taipei Medical University Hospital trials
Trials by the same sponsor.
- NCT07294469 — Menthol for Improving Movement and Sleep in Parkinson's Disease Patients · Phase 2 · not yet recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT05830578 — Clinical Validation of the Electrocardiogram Measurement · unknown
- NCT05877079 — TRPM8 in Acute Ischemic Stroke by Topical Menthol · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05455528 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Hospital
- Last refreshed: 13 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing